Olema Pharmaceuticals, Inc.
Business
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer and other hormone-driven cancers. The company's lead product candidate, palazestrant, is an oral small molecule functioning as both a complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in pivotal Phase 3 trials for ER-positive/HER2-negative metastatic breast cancer as monotherapy and in combination with CDK4/6 inhibitors. Olema's second product candidate, OP-3136, is a KAT6 inhibitor in early-stage clinical development for breast and other solid tumors. The company operates without approved products, relies on third-party contract manufacturing, and intends to commercialize either independently or through partnerships.
Summary from 10-K filed 2026-03-16
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 158 | 125 | 86 | 82 | 51 | |
| General and administrative | 21 | 18 | 19 | 25 | 20 | |
| Total operating expenses | 179 | 142 | 105 | 107 | 71 | |
| Loss from operations | −179 | −142 | −105 | −107 | −71 | |
| Interest income | 16 | 13 | 8 | 2 | 442,000 | |
| Other income | 23,000 | 102,000 | −19,000 | −27,000 | −47,000 | |
| Total other income | 16 | 13 | 8 | 2 | 395,000 | |
| Net loss | −162 | −129 | −97 | −105 | −71 | |
| Net loss per share, basic (in dollars per share) | −1.87 | −2.2 | −2.14 | −2.62 | −1.8 | |
| Net loss per share, diluted (in dollars per share) | −1.87 | −2.2 | −2.14 | −2.62 | −1.8 | |
| Weighted average shares used to compute net loss per share, basic (in shares) | 87 | 59 | 45 | 40 | 40 | |
| Weighted average shares used to compute net loss per share, diluted (in shares) | 87 | 59 | 45 | 40 | 40 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 48 | 139 | 69 | 24 | 14 | |
| Marketable securities | 457 | 295 | 193 | 181 | 273 | |
| Prepaid expenses and other current assets | 10 | 4 | 5 | 4 | 3 | |
| Total current assets | 515 | 438 | 267 | 209 | 291 | |
| Operating lease right-of-use assets | 1 | 1 | 2 | 2 | 3 | |
| Other assets and long-term deposits | 17 | 11 | 8 | 4 | — | |
| Total assets | 533 | 451 | 277 | 216 | 296 | |
| Accounts payable | 9 | 4 | 3 | 374,000 | 23,000 | |
| Operating lease liabilities, current | 1 | 1 | 988,000 | 1 | 931,000 | |
| Other current liabilities (Note 6) | 41 | 36 | 18 | 15 | 8 | |
| Total current liabilities | 52 | 42 | 22 | 17 | 9 | |
| Operating lease liabilities, net of current portion | 69,000 | 257,000 | 1 | 2 | 2 | |
| Long-term borrowing | 3 | 0 | — | — | — | |
| Total liabilities | 55 | 42 | 23 | 18 | 11 | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding as of December 31, 2025 and 2024. | — | — | — | — | — | |
| Common stock, $0.0001 par value; 490,000,000 shares authorized as of December 31, 2025 and 2024; 81,376,449 and 74,312,608 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 8,000 | 7,000 | 4,000 | 3,000 | 3,000 | |
| Additional paid-in capital | 1,075 | 844 | 559 | 408 | 389 | |
| Accumulated other comprehensive income | 621,000 | 143,000 | 347,000 | −2 | −149,000 | |
| Accumulated deficit | −598 | −435 | −306 | −209 | −104 | |
| Total stockholders' equity | 479 | 409 | 254 | 198 | 285 | |
| Total liabilities and stockholders' equity | 533 | 451 | 277 | 216 | 296 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −162 | −129 | −97 | −105 | −71 | |
| Depreciation and amortization expense | 490,000 | 393,000 | 377,000 | 357,000 | 163,000 | |
| Non-cash lease expense | 1 | 1 | 1 | 1 | 1 | |
| Non-cash interest income on marketable securities | −6 | −8 | — | — | — | |
| Stock-based compensation expense, including employee stock purchase plan expense | 18 | 23 | 17 | 19 | 16 | |
| Loss on disposal of equipment | — | 9,000 | 111,000 | — | — | |
| Prepaid expenses and other current assets | −5 | −429,000 | 694,000 | −2 | −40,000 | |
| Other assets and long-term deposits | −6 | −3 | −5 | −1 | — | |
| Accounts payable | 5 | 3 | 2 | 351,000 | −683,000 | |
| Other current liabilities | 11 | 11 | 3 | 7 | 5 | |
| Operating lease liabilities | −1 | −1 | −1 | −1 | −988,000 | |
| Net cash used in operating activities | −147 | −104 | −84 | −82 | −51 | |
| Purchase of equipment | — | −159,000 | — | −363,000 | −2 | |
| Maturities of marketable securities | 345 | 302 | 251 | 306 | 213 | |
| Purchases of marketable securities | −501 | −395 | −256 | −214 | −487 | |
| Net cash used in investing activities | −156 | −94 | −5 | 91 | −275 | |
| Proceeds from issuance of shares upon follow-on public offering, net of issuance costs of $13,110 | 205 | — | — | — | — | |
| Proceeds from issuance of shares under at-the-market offering, net of issuance costs of $166 | — | 23 | — | — | — | |
| Proceeds from 2024 private placement, net of issuance costs of $6,498 | — | 244 | 130 | — | — | |
| Payment of issuance costs for shares issued under 2024 private placement | −7 | — | — | — | — | |
| Proceeds from borrowings under Credit Facility (Note 13) | 3 | — | — | — | — | |
| Proceeds from exercise of stock options | 8 | 2 | 3 | 146,000 | 670,000 | |
| Proceeds from issuance of common stock under employee stock purchase plan | 1 | 859,000 | 1 | 330,000 | 721,000 | |
| Net cash provided by financing activities | 211 | 269 | 133 | 476,000 | 1 | |
| Net (decrease) increase in cash and cash equivalents | −91 | 71 | 45 | 10 | −325 | |
| Exchange common stock shares for pre-funded warrants | 29 | 31 | — | — | — | |
| Right-of-use asset obtained in exchange for operating lease liabilities | 896,000 | 0 | — | — | — | |
| Unpaid issuance costs related to follow-on offering and 2024 private placement | 578,000 | 7 | — | — | — | |
| Research and development project deposit applied against study invoices | 177,000 | 748,000 | — | — | — | |
| System implementation cost included in other current liabilities | −95,000 | −337,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Olema Pharmaceuticals, Inc.'s CIK number?
Olema Pharmaceuticals, Inc.'s SEC CIK number is 0001750284 (1750284). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Olema Pharmaceuticals, Inc.'s SEC filings?
All of Olema Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Olema Pharmaceuticals, Inc. last report earnings?
Olema Pharmaceuticals, Inc. (OLMA) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-218142). This is Olema Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Olema Pharmaceuticals, Inc.'s most recent earnings 8-K?
Olema Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-218142. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Olema Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →